HC Wainwright Research Analysts Cut Earnings Estimates for ASP Isotopes Inc. (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI) – HC Wainwright decreased their FY2024 earnings estimates for shares of ASP Isotopes in a report issued on Wednesday, April 17th. HC Wainwright analyst H. Ihle now forecasts that the company will earn ($0.11) per share for the year, down from their prior estimate of $0.07. HC Wainwright currently has a “Buy” rating and a $5.50 price objective on the stock. The consensus estimate for ASP Isotopes’ current full-year earnings is $0.07 per share.

ASP Isotopes Price Performance

Shares of NASDAQ:ASPI opened at $3.09 on Friday. ASP Isotopes has a 52 week low of $0.28 and a 52 week high of $4.97. The company’s 50 day moving average is $3.67 and its two-hundred day moving average is $2.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.85 and a quick ratio of 1.85.

Insider Buying and Selling at ASP Isotopes

In related news, Director Robert John Andrew Ryan bought 15,596 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were purchased at an average cost of $2.35 per share, with a total value of $36,650.60. Following the transaction, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 26.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ASPI. Millennium Management LLC purchased a new position in shares of ASP Isotopes in the 4th quarter valued at $49,000. Armistice Capital LLC acquired a new stake in ASP Isotopes during the 1st quarter worth $2,702,000. Renaissance Technologies LLC acquired a new stake in ASP Isotopes during the 2nd quarter worth $272,000. HTLF Bank acquired a new stake in ASP Isotopes during the 4th quarter worth $141,000. Finally, Rathbones Group PLC acquired a new stake in ASP Isotopes during the 4th quarter worth $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.